New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

Trump’s order to halt all international aid programs has left thousands of workers in limbo and millions of beneficiaries in ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Updated recommendations were issued by the IAS-USA regarding the use of ART for treatment and prevention of HIV in adult populations.

The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The Food and Drug Administration approved the pill from Vertex Pharmaceuticals for acute pain that often occurs after surgery ...

Researchers from the HUN-REN Biological Research Centre, Szeged (Hungary), have made a concerning discovery about the future of antibiotics.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...